Hereditary Angioedema – HAE
EPIC Pharma’s specialised teams in Immunology, support an innovative new treatment option for HAE.
HAE is a rare genetic disease characterised by recurrent sudden attacks of oedema of the skin or the mucous membranes. HAE affects between 1 in 10,000 and 1 in 50,000 people.
HAE is caused by an inherited deficiency of C1-esterase inhibitor (C1-INH), a protein which has a regulatory role in the classic complement pathway and in the coagulation, fibrinolytic, and kallikrein–kinin (contact-system) cascades. In HAE, C1-INH deficiency results in an increased release of the peptide hormone bradykinin, the key mediator of HAE symptoms. Bradykinin is released locally in response to trauma, injury or other triggers, in the affected area. It binds to the bradykinin B2 receptor at the thin layer of endothelial cells that line the interior surface of the blood vessel wall, causing the vessels to dilate and become more permeable. As a result, fluid passes into the surrounding tissue and leads to oedema formation.
Oncology & Haematology – Unlicensed Medicines
EPIC Pharma specialised team provides Medical Science Liaison and Market Access support for a no. of unlicensed medicines in the Haematology Oncology area.
Oncology & Haematology – Supportive Care
EPIC Pharma specialised team distribute and promote a no. of Supportive Care Medicines and Medical Devices to Healthcare Professionals and ultimately patients undergoing treatment for cancer.